Barclays Maintains Underweight on Pacific Biosciences, Raises Price Target to $1.5
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Barclays analyst Luke Sergott maintains Pacific Biosciences (NASDAQ:PACB) with a Underweight and raises the price target from $1 to $1.5.
Barclays analyst Luke Sergott maintains Pacific Biosciences (NASDAQ:PACB) with a Underweight and raises the price target from $1 to $1.5.